ICD-10 Chapter VII: Diseases of the eye, adnexa

Worldwide Dry Eye Disease Industry to 2025 - Featuring AbbVie, Alcon & VISUfarma Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 16, 2020
Health, Optical, Medicine, RTT, Ophthalmology, Companies, Blindness, Allergan, Cataract, ICD-10 Chapter VII: Diseases of the eye, adnexa, AbbVie Inc., Disease

These are widely available and rapidly relieve the symptoms and signs of moderate and severe dry eye diseases.

Key Points: 
  • These are widely available and rapidly relieve the symptoms and signs of moderate and severe dry eye diseases.
  • These drugs are highly useful in short-term efficacy, and thus, are prescribed mostly for acute cases of dry eye diseases.
  • However, the long-term usage of these drugs has major side effects, such as intraocular pressure elevation and cataract progression.
  • Two of the major companies established in this segment are Bausch Health and AbbVie Inc (Allergan Plc).

Guardion Health Sciences Announces Submission of Patent Application for Treatment of Certain Underlying Conditions Related to Eye Disease

Retrieved on: 
Wednesday, July 8, 2020
Intellectual property law, United States patent law, Provisional application, Glaucoma, Patent, United States Patent and Trademark Office, ICD-10 Chapter VII: Diseases of the eye, adnexa

GlaucoCetin provides nutritional support to help manage certain underlying conditions related to eye disease.

Key Points: 
  • GlaucoCetin provides nutritional support to help manage certain underlying conditions related to eye disease.
  • The Company previously submitted a provisional patent to the U.S. Patent and Trademark Office on June 11, 2019.
  • Dr. Robert Ritch, M.D., the inventor of the formula, is a world-renowned glaucoma scientist and clinician and is a member of the Guardion Medical Advisory Board.
  • Guardion will recognize this shipment in operating revenues for the three months ended June 30, 2020.

OliX Pharmaceuticals Signs Agreement with LGC Biosearch Technologies to Accelerate Production of Asymmetric siRNA for the Treatment of Sub-Retinal Fibrosis and Wet Macular Degeneration

Retrieved on: 
Tuesday, June 16, 2020
Ophthalmology, Medicine, Clinical medicine, Medical signs, Macular degeneration, RTT, Senescence, Macular edema, Choroidal neovascularization, ICD-10 Chapter VII: Diseases of the eye, adnexa, Maculopathy, Metamorphopsia

Under the terms of the agreement, LGC will produce the active pharmaceutical ingredients for the preclinical and clinical study of OLX301D program, for the treatment of sub-retinal fibrosis and wet macular degeneration.

Key Points: 
  • Under the terms of the agreement, LGC will produce the active pharmaceutical ingredients for the preclinical and clinical study of OLX301D program, for the treatment of sub-retinal fibrosis and wet macular degeneration.
  • The OLX301D program is a first-in-class treatment that may treat choroidal neovascularization and sub-retinal fibrosis in patients with wet macular degeneration.
  • Sub-retinal fibrosis is caused by the development of disciform scar and fibrosis underneath the retina which can cause vision loss through macular edema and detachment.
  • Wet macular degeneration is a chronic eye disorder that causes blurred vision or a blind spot in your visual field.

Emerald Bioscience to Present at the 9th Annual Glaucoma 360 New Horizons Forum and BIO CEO & Investor Forum

Retrieved on: 
Thursday, January 30, 2020
Blindness, Glaucoma, RTT, ICD-10 Chapter VII: Diseases of the eye, adnexa

Long Beach, CA, Jan. 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced that Dr. Brian Murphy, Chief Executive Officer, Emerald Bioscience will present at the upcoming 9th Annual Glaucoma 360 New Horizons Forum and BIO CEO & Investor Conference.

Key Points: 
  • Long Beach, CA, Jan. 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced that Dr. Brian Murphy, Chief Executive Officer, Emerald Bioscience will present at the upcoming 9th Annual Glaucoma 360 New Horizons Forum and BIO CEO & Investor Conference.
  • Dr. Brian Murphy will present an overview of Emerald Biosciences cannabinoid pipeline for ocular diseases, including its lead candidate NB1111 for the management of glaucoma, at the 9th Annual Glaucoma 360 New Horizons Forum being held on Friday, February 7, 2020 at the Grand Hyatt Union Square in San Francisco, CA.
  • This meeting, held by the Glaucoma Research Foundation, brings together key clinical and industry leaders in a unique exchange on research innovation and advances in glaucoma treatment.
  • Details of the presentation are as follows:
    The 2020 meeting will feature more than 60 speakers from companies developing innovative glaucoma therapies and diagnostics.

Akari Therapeutics Announces Preclinical Ophthalmic Data Showing Nomacopan Reduces Both Vascular Endothelial Growth Factor (VEGF) and Retinal Inflammation Supporting Nomacopan as a Potential Treatment Option for Back-of-the-Eye Diseases

Retrieved on: 
Monday, January 27, 2020
Ophthalmology, Vision, Medicine, Blindness, Diabetes, Diabetic retinopathy, Breakthrough therapy, Retinopathy, Macular degeneration, Retina, ICD-10 Chapter VII: Diseases of the eye, adnexa, Gene therapy of the human retina

By inhibiting VEGF and complement, and reducing retinal inflammation, nomacopan has the potential to treat multiple pathways implicated in back-of-the-eye diseases.

Key Points: 
  • By inhibiting VEGF and complement, and reducing retinal inflammation, nomacopan has the potential to treat multiple pathways implicated in back-of-the-eye diseases.
  • PAS-nomacopan, with its longer half-life, offers potential for less frequent injections (intravitreal dosing), which is critical in the treatment of back-of-the-eye diseases.
  • Treatment of back-of-the-eye diseases, including angiogenic ocular diseases with new blood vessel growth such as diabetic retinopathy and wet age-related macular degeneration (AMD), is a multi-billion dollar market.
  • Akari believes that the dual action of nomacopan on both C5 and LTB4 may be beneficial in AKC and BP.